Vertaling van "merger which is governed under the swiss " (Nederlands → Frans) :

This merger, which is governed under the Swiss Merger Act, proposes a fixed exchange ratio of 2.80 Novartis shares for each remaining Alcon share.
Soumise à la loi fédérale suisse sur les fusions, cette fusion propose une parité fixe de 2,80 actions Novartis pour chacune des actions Alcon restantes.

Novartis believes this merger, which is governed under the Swiss Merger Act, is in the interest of all stakeholders and will provide the needed clarity on Alcon’s future.
Novartis est convaincu que cette fusion, qui sera réalisée conformément à la loi fédérale suisse sur la fusion, est dans l’intérêt de toutes les parties prenantes en apportant la clarté nécessaire à l’avenir d’Alcon.

This merger, which will be implemented under the Swiss Merger Act, is in the interest of all stakeholders and will provide the needed clarity on Alcon’s future.
Cette fusion, qui sera réalisée conformément à la loi fédérale sur la fusion, est dans l'intérêt de toutes les parties prenantes en clarifiant l’avenir d’Alcon.

Under Swiss law, Novartis has the right to vote its Alcon stake in favor of the proposed merger.
En vertu de la loi suisse, Novartis a le droit d’utiliser les droits de vote que lui confère sa participation dans Alcon en faveur de la fusion proposée.

Following the merger under Swiss law, Alcon will become a new division that incorporates CIBA Vision and certain Novartis ophthalmic medicines.
A la suite de la fusion en droit suisse, Alcon deviendra une nouvelle division de Novartis qui intégrera CIBA Vision et certains médicaments ophtalmologiques de Novartis.

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Corporate – Alcon On April 7, Novartis announced an agreement with Nestlé S.A. under which Novartis obtained rights to acquire majority ownership of Alcon Inc (NYSE: ACL), a Swiss-registered company listed only on the New York Stock Exchange.
Corporate – Alcon Le 7 avril, Novartis a annoncé avoir conclu un accord avec Nestlé S.A. lui donnant le droit d’acquérir une participation majoritaire dans Alcon Inc (NYSE: ACL), une société enregistrée en Suisse mais cotée uniquement à la Bourse de New York.

Corporate – Alcon On April 7, Novartis announced an agreement with Nestlé S.A. under which Novartis obtained rights to acquire in two steps majority ownership of Alcon Inc (NYSE: ACL), a Swiss-registered company listed only on the New York Stock Exchange.
Corporate – Alcon Le 7 avril, Novartis a annoncé avoir conclu un accord avec Nestlé S.A. lui donnant le droit d’acquérir, en deux étapes, une participation majoritaire dans Alcon Inc (NYSE: ACL), une société enregistrée en Suisse mais cotée uniquement à la Bourse de New York.